A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung  by Leighl, Natasha B. et al.
ORIGINAL ARTICLE
A Multicenter, Phase 2 Study of Vascular Endothelial
Growth Factor Trap (Aflibercept) in Platinum- and
Erlotinib-Resistant Adenocarcinoma of the Lung
Natasha B. Leighl, MD, MMSc,* Luis E. Raez, MD, FACP,† Benjamin Besse, MD, PhD,‡
Peter J. Rosen, MD,§ Fabrice Barlesi, MD, PhD, E. Massarelli, MD,¶ Nashat Gabrail, MD,#
Lowell L. Hart, MD, FACP,** Kathy S. Albain, MD,†† Lloyd Berkowitz, MD,‡‡ Ostap Melnyk, MD,§§
Frances A. Shepherd, MD,* Lars Sternas, MD, PhD, Judie Ackerman, RN, MPA, OCN,
Zhenming Shun, PhD, Vincent A. Miller, MD,¶¶ and Roy S. Herbst, MD, PhD, FACP¶
Introduction: Aflibercept (vascular endothelial growth factor [VEGF]
trap), a recombinant fusion protein, blocks the activity of VEGF-A and
placental growth factor and has demonstrated activity in pretreated
patients with lung cancer in a phase I trial. This study evaluated the
efficacy and safety of intravenous aflibercept in patients with plat-
inum- and erlotinib-resistant lung adenocarcinoma.
Methods: An open-label, single arm, multicenter trial was con-
ducted, with the primary end point of response rate (modified
RECIST). Additional endpoints included safety, duration of re-
sponse, progression-free survival, and overall survival. Patients with
platinum- and erlotinib-resistant lung adenocarcinoma were eligible.
Aflibercept 4.0 mg/kg intravenous every 2 weeks was administered
until progression of disease or intolerable toxicity.
Results: Ninety-eight patients were enrolled; 89 were evaluable for
response. Median age was 60 years, 41% were men with Eastern
Cooperative Oncology Group performance status 0/1/2 in 35/55/9%
of patients. The overall response rate was 2.0%, (95% confidence
interval, 0.2–7.2%). Median progression-free survival was 2.7 months,
and overall was survival 6.2 months. Six- and 12-month survival rates
were 54 and 29%, respectively. A median of four cycles was adminis-
tered (range 1–22). Common grade 3/4 toxicities included dyspnea
(21%), hypertension (23%), and proteinuria (10%). Two cases of grade
5 hemoptysis were reported, and one case each of tracheoesophageal
fistula, decreased cardiac ejection fraction, cerebral ischemia, and re-
versible posterior leukoencephalopathy.
Conclusions: Aflibercept has minor single agent activity in heavily
pretreated lung adenocarcinoma, and is well tolerated, with no
unexpected toxicities. Further studies evaluating aflibercept in lung
cancer, in combination with chemotherapy and other targeted ther-
apies, are ongoing.
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Aflibercept (vascular endothelial growth factor [VEGF]trap) is a recombinant fusion protein, consisting of human
VEGF receptor 1 extracellular domain 2 and receptor 2
extracellular domain 3, fused to the hinge region of the
human IgG1 Fc domain. Potential advantages of aflibercept
over other VEGF inhibitors include its high VEGF-A binding
affinity (approximately 1000-fold greater than bevacizumab),
the ability to bind VEGF-B, as well as placental growth
factors 1 and 2, and a longer half-life.1 It is currently un-
known whether these advantages will translate into clinical
superiority over other VEGF inhibitors, such as bevacizumab.
In a phase 1 trial of aflibercept administered subcutaneously,
one durable partial response was seen in a heavily pretreated
patient with adenocarcinoma with bronchoalveolar features.2
Toxicities seen in phase I trials of subcutaneously and intra-
venously administered aflibercept include hypertension and
proteinuria, similar to other VEGF inhibitors.1–3
VEGF-mediated signaling is important in the develop-
ment and progression of lung cancer and has been shown to
be prognostic.4–11 In two large randomized trials of first-line
chemotherapy in advanced non-small cell lung cancer
(NSCLC), bevacizumab in combination with chemotherapy
has been shown to improve outcome over chemotherapy
alone, including improved survival in one trial.12,13 In addi-
tion, a recently reported trial of second-line erlotinib, an
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epidermal growth factor tyrosine kinase inhibitor (EGFR
TKI), plus bevacizumab or placebo demonstrated that the
erlotinib/bevacizumab combination yielded superior response
rates, and better progression-free survival (PFS), although
overall survival (OS) was not improved in this trial.14 As
such, inhibition of VEGF-mediated signaling in NSCLC is
the first targeted therapy that reproducibly improves out-
comes, i.e. response, PFS, and even OS, when added to
cytotoxic chemotherapy.
In this study, we examined the efficacy and safety of
aflibercept as a single agent in previously treated, platinum-
and erlotinib-resistant adenocarcinoma of the lung.
MATERIALS AND METHODS
This was an open-label, single arm, multicenter phase 2
trial using a two-stage Simon design. All participating centers
had Institutional Review Board approval to conduct the
study. All patients provided written informed consent to
participate.
Study Population
Patients were eligible to participate if they had advanced
or metastatic adenocarcinoma of the lung (to decrease theoretical
risk of pulmonary hemorrhage); received at least two previous
therapies for advanced disease; were platinum- and erlotinib-
resistant, defined as disease relapse or progression during or after
treatment, or drug intolerance; measurable disease by RECIST15;
age 18 or older; Eastern Cooperative Oncology Group perfor-
mance status 0–2; no toxicities related to previous therapy for
National Cancer Institute Common Toxicity Criteria version
3.0  grade 1; adequate organ and bone marrow function,
including a urine protein:creatinine ratio less than or equal to 1.
Patients were excluded for squamous cell histology,
previous VEGF, or VEGF receptor-2 inhibitor therapy except
bevacizumab, uncontrolled hypertension, significant comor-
bidities including thromboembolic events within 6 months, a
history of brain or meningeal metastases, spinal cord com-
pression, clinically significant hemoptysis or underlying co-
agulopathy, active human immunodeficiency virus infection,
pregnancy or breast-feeding, or inability to provide informed
consent.
Study Treatment
Patients were treated with intravenous (IV) aflibercept
at a dose of 4.0 mg/kg administered over 1 hour by infusion
pump every 14 days.
Dose reduction was permitted for uncontrolled grade 3
hypertension, proteinuria, and any drug-related toxicity that
met criteria of a serious adverse event, or resulted in more
than 2 weeks delay in study treatment. The first dose reduc-
tion was to 3.0 mg/kg and the second to 2.0 mg/kg every 2
weeks. Patients requiring more than two dose reductions were
removed from study.
Primary and Secondary Endpoints
The primary end point of the study was to determine the
objective response rate of aflibercept 4.0 mg/kg IV every 2
weeks using modified RECIST. RECIST15 was modified to
subtract the longest cavitation diameters from the longest
unidimensional measurements of the cavitated target lesions.
All responses were to be confirmed in 4 to 6 weeks. Second-
ary objectives include assessment of the duration of response,
PFS, OS, and safety.
Evaluations on Therapy
At baseline, patients were evaluated with history and
physical examination, blood work including hematology and
biochemistry, urinalysis for proteinuria, and computed to-
mography, or magnetic resonance imaging of the brain, chest,
abdomen, and pelvis. These were repeated every 2 weeks
except radiologic imaging which was repeated every 4 weeks
or two cycles.
Statistical Considerations
A Simon two-stage design was used to test the null
hypothesis that the true response rate was less than or equal
to 5% versus the alternative hypothesis that the true response
rate was more than or equal to 15%, with a one-sided alpha
level of 0.05 and 90% power. If more than or equal to three
objective responses were seen in the first 37 patients
evaluated, an additional 47 evaluable patients were to be
accrued. If fewer responses were seen, the trial was to be
terminated unless data analysis suggested that further explo-
ration was warranted. The null hypothesis would be rejected
if more than or equal to eight responses were seen in the 84
evaluable patients.
Descriptive statistics were used to summarize safety
and efficacy outcomes along with 95% confidence intervals
(CI) where possible. The Kaplan-Meier method was used to
estimate PFS and OS statistics. OS was calculated from the date
of registration until the date of death or last date the patient was
known to be alive. PFS was calculated from the date of
registration until the first date of progression or death. Pa-
tients who were removed from treatment due to reasons other
than progression or death were censored for these time-to-
event analyses.
Exploratory analyses were performed to assess the
association between hypertension on therapy (none, grade
1/2, and grade 3) and outcome (PFS and OS).
RESULTS
Ninty-eight patients from 35 institutions in Canada,
France, and the United States were enrolled between Febru-
ary 2006 and August 2007. Two patients did not receive
study drug, 89 were evaluable for efficacy, and 96 were
included in the safety analysis. Patient characteristics includ-
ing prior treatment details are listed in Table 1. Most patients
were good performance status (91% Eastern Cooperative
Oncology Group 0 or 1), and 69% had received at least three
previous lines of therapy. Twenty patients had received
previous bevacizumab. The median time from initial diagno-
sis for the cohort was 2.4 years (range 0.5–11.4 years), and
the median time from last treatment or relapse until study
entry was 1 month, with 91% of patients enrolling within 3
months. Based on observed responses and information about
stable disease, the Independent Data Monitoring Committee
recommended continued accrual into the second stage.
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Response Rates
The overall response rate by intent-to-treat analysis was
2.0%, (95% CI, 0.2–7.2%), using traditional and modified
RECIST by investigator assessment, both partial responses.
After accrual to stage 1, the data safety monitoring committee
recommended that expansion to stage 2 was warranted, based
on the rate and duration of stable disease observed in this
heavily pretreated population. Sixty-seven percent of patients
had stable disease at their first evaluation (30 days). A
number of patients had prolonged disease stabilization and a
waterfall plot reflecting the best percentage reduction from
baseline using independent radiology assessment of modified
RECIST measurements is shown in Figure 1.
PFS and OS
The median time to progression was 2.7 months (95% CI,
2.2–3.4 months), with 18% of patients progression free at 6
months (by investigator assessment using RECIST, shown in
Figure 2). Median survival was 6.2 months (95% CI, 4.8–11.4
months) with 54% of patients alive at 6 months and 29% at 1
year (Figure 3). There was a trend for better OS in patients who
developed grade 3 hypertension on aflibercept (n  22) versus
those who did not develop hypertension (n  60).
Dose Delivery
The median number of cycles administered was four
(range 1–22) with a median duration of exposure of 9 weeks
(2–60 weeks). Median cumulative dose was 16 mg/kg (range
4–87) with a mean relative dose intensity of 93%, (standard
deviation, 0.11). Twenty-three patients experienced one dose
delay and 15 were delayed for more than one cycle. Only 11
patients required dose reduction.
Safety
The most common grades 3 and 4 toxicities seen
included proteinuria, hypertension, and dyspnea. Other com-
mon toxicities included fatigue, headache, arthralgia, muscu-
FIGURE 1. Tumor burden by wa-
terfall plot. Best reduction as per-
cent change from baseline using
modified RECIST per independent
radiology measurements.
TABLE 1. Patient Demographics
Characteristic N  98
Age (yr)













Erlotinib or other EGFR inhibitor 97
Bevacizumab 20
Two previous lines 29
Three previous lines 31
4 previous lines 38






Previous surgery (%) 50
Previous radiation therapy (%) 49
Leighl et al. Journal of Thoracic Oncology • Volume 5, Number 7, July 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer1056
loskeletal pain, dysphonia, epistaxis, and low-grade hemop-
tysis (Table 2). There were two treatment-related fatal
adverse events on study, both grade 5 hemoptysis. A 64-year-
old man developed nonmalignant bronchial ulcerative lesions
seen on bronchoscopy after 20 cycles of aflibercept, and
subsequent fatal hemoptysis 17 days postbronchoscopy, 30
days after his last treatment. A 61-year-old woman, previ-
ously treated with five lines of systemic therapy and radio-
therapy, developed grade 5 hemoptysis at home on day 5 after
cycle 8 of aflibercept. She had been evaluated with laryngos-
copy the day before for increasing cough and hoarseness,
with no abnormalities seen in the upper airway. Other serious
adverse events deemed related to aflibercept included one
case each of acquired tracheoesophageal fistula (cycle 2
and day 36), decreased left ventricular ejection fraction
(35% after cycle 2), cerebral ischemia (cycle 4 and day 9),
and reversible posterior leukoencephalopathy syndrome
(cycle 1, day 14). The most common reason for study
discontinuation was progressive disease (53%), followed
by adverse events (20%). No patient stopped therapy for
uncontrolled hypertension.
DISCUSSION
Aflibercept administered every 2 weeks at a dose of 4
mg/kg demonstrated minor single agent activity with evi-
dence of disease stabilization in a heavily pretreated popula-
tion of lung adenocarcinoma patients, who had received both
platinum-based and EGFR inhibitor therapy. Aflibercept was
well tolerated, with no unexpected toxicities. However,
despite careful restrictions on eligibility to include only
adenocarcinoma patients, and those without significant
hemoptysis, the rate of fatal hemoptysis was 2%, consis-
tent with what has been seen in other trials with bevaci-
zumab and sunitinib.12,13,16
Although the overall response rate was disappointing, a
substantial number of patients experienced at least some
tumor regression, as shown in Figure 1. This is despite its use
as a single agent in a heavily pretreated study population,
with 70% of patients having received 3 or more lines of
systemic therapy for advanced NSCLC. In addition, response
is likely a suboptimal end point to measure activity of VEGF
inhibitors, given the expectation that most of their effect as
single agents would be cytostatic in nature. The frequency
cavitation of tumor lesions on VEGF inhibitors rather than
unidimensional tumor reduction also complicates the use of
FIGURE 2. Progression-free survival (N  98). Median pro-
gression-free survival 2.7 months; 6-month progression-free
survival rate 18%.
FIGURE 3. Overall survival (N  98). Median survival 6.2
months; 6-month survival 54%; 12-month survival 29%.






















Musculoskeletal pain 12 1
Diarrhea 12 2
Fever 12 0
Urinary tract infection 12 1
Hemoptysis 13 2a
CNS disordersb 2 2
a Both grade 5.
b One case of cerebral ischemia, one reversible posterior leukoencephalopathy.
CNS, central nervous system.
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tumor response as a reliable marker of promising activity.
However, in a review undertaken by the NCIC Clinical Trials
Group of patients treated with VEGF inhibitors, use of
modified
RECIST did not impact substantially on overall response
rates determined using classic RECIST.17 Alternate methods
of measurement, such as volumetric computed tomography
imaging18 or functional imaging, may provide better end-
points to screen for activity with this class of agents, along
with time to progression. The 6-month PFS rate of 18% and
6- and 12-month survival rates of 54% and 29%, respectively,
are clearly promising in such a heavily pretreated population,
although patient selection is a potential confounder.
Currently, there are also no data supporting single agent
activity of bevacizumab in advanced NSCLC, despite the fact
that bevacizumab has been shown to improve outcomes when
added to first-line platinum-based chemotherapy.12,13,19 In
contrast, several VEGF tyrosine kinase inhibitors have dem-
onstrated single agent activity in less heavily pretreated
NSCLC patients, with response rates ranging from 7 to 10%
with sunitinib, axitinib, vatalanib, and vandetanib and median
time to progression from 2.4 to 5.8 months in phase II
studies.16,20–22 Sorafenib, another multitargeted tyrosine ki-
nase inhibitor,23,24 did not induce responses as a single agent
in pretreated NSCLC nor has it been shown to add to first-line
chemotherapy.25 It remains unclear whether there may be
potential differences in activity and tumor penetration be-
tween the small molecule VEGF tyrosine kinase inhibitors
compared with larger molecules such as aflibercept and
bevacizumab. Despite the low response rate in this study, PFS
in this extensively pretreated patient sample was comparable
to other VEGF inhibitor studies in advanced NSCLC.
Further questions remain regarding the incorporation of
molecular markers to select patients who may benefit most
from VEGF inhibitor therapy. At the present time, patient
selection remains driven by perceived safety concerns. To
decrease the risk of severe pulmonary hemorrhage, several
trials of VEGF inhibitors have excluded patients with squa-
mous cell histology, proximal lung tumors with central cav-
itation or those with significant hemoptysis at baseline, in-
cluding the current trial.12,13,18,26 Thus, to understand the
potential activity of aflibercept in squamous cell histology,
separate studies would need to be conducted in that popula-
tion, recognizing the potential for incremental toxicity. There
are several molecular markers of interest, but none has yet
demonstrated ability to predict significant benefit from VEGF
inhibitor therapy. These include baseline plasma VEGF lev-
els, associated with greater response but not OS, and low
ICAM-1 levels associated with better PFS in bevacizumab-
treated patients in the E4599 randomized trial.27 Hanrahan et
al.28 have demonstrated in studies of vandetanib that low
baseline VEGF levels in advanced NSCLC may predict for
better PFS with vandetanib versus gefitinib or docetaxel. Also
treatment with VEGF inhibitors may lead to different patterns
of cytokine and angiogenic factors than chemotherapy treat-
ment, that may correlate with outcome and potentially be
useful in the future as predictive markers of treatment resis-
tance and/or benefit.29,30
Functional single nucleotide polymorphisms of VEGF
are also of interest. Variant alleles of 936CT and
405GC single nucleotide polymorphisms have been as-
sociated with lower plasma VEGF levels and survival in
patients with resected early stage NSCLC.31 VEGF genotypes
(VEGF-2578AA, VEGF-1154) may be associated with better
survival in bevacizumab-treated patients as well as differen-
tial rates of hypertension, seen in the E2100 randomized trial
of paclitaxel  bevacizumab in advanced breast cancer.32 The
development of hypertension during VEGF inhibitor therapy has
been associated with improved outcomes, including better sur-
vival.33–36 This study also demonstrates a trend to better
survival in those who developed grade 3 hypertension on
treatment, although not statistically significant given the
small numbers in the trial. These areas are worthy of further
study, to help better define their potential role in predicting
benefit and toxicity from VEGF inhibitor therapy.
Combinations of VEGF inhibitors with other targeted
agents remain promising, including improved PFS in a study
of second-line erlotinib plus bevacizumab compared with
erlotinib alone.14 Aflibercept is currently under development
in other tumor types including colorectal, pancreas, prostate
and ovarian cancers, where activity has been seen. In
NSCLC, a phase III randomized trial, VITAL, that com-
pares second-line docetaxel plus aflibercept or placebo, is
ongoing. This trial may help to define the utility of afliber-
cept (and ongoing VEGF inhibition) in patients who have
previously been treated with bevacizumab and first-line
chemotherapy.
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